Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ROCK1 | Q13464 | 20/20 | 1.00 |
| ▸ | ROCK2 | O75116 | 18/20 | 1.00 |
| ▸ | PRKACA | P17612 | 1/20 | 0.73 |
| ▸ | SGK1 | O00141 | 1/20 | 0.71 |
| ▸ | AKT1 | P31749 | 1/20 | 0.71 |
| ▸ | GSK3B | P49841 | 1/20 | 0.71 |
| ▸ | LIMK1 | P53667 | 1/20 | 0.71 |
| ▸ | TNK2 | Q07912 | 1/20 | 0.71 |
| ▸ | DMPK | Q09013 | 1/20 | 0.71 |
| ▸ | MYLK | Q15746 | 1/20 | 0.71 |
| ▸ | CDC42BPA | Q5VT25 | 1/20 | 0.71 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2554639 | 0.90 | ROCK1 (1.00) | ROCK1ROCK2 | |
| SCHEMBL2554182 | 0.89 | ROCK1 (0.81) | ROCK1ROCK2PRKACA | |
| SCHEMBL29431307 | 0.88 | ROCK1 (1.00) | ROCK1ROCK2PRKACASGK1AKT1 | |
| SCHEMBL2560201 | 0.88 | ROCK1 (1.00) | ROCK1ROCK2PRKACASGK1AKT1 | |
| SCHEMBL2555028 | 0.87 | ROCK1 (1.00) | ROCK1ROCK2SGK1AKT1GSK3B | |
| Hydrochloric Acid SCHEMBL29633094 | 0.87 | ROCK1 (0.98) | ROCK1ROCK2PRKACASGK1AKT1 | |
| SCHEMBL2554347 | 0.87 | ROCK1 (1.00) | ROCK1ROCK2SGK1AKT1GSK3B | |
| SCHEMBL2560469 | 0.87 | ROCK2 (1.00) | ROCK1ROCK2SGK1AKT1GSK3B | |
| Hydrochloric Acid SCHEMBL17836965 | 0.87 | ROCK1 (0.98) | ROCK1ROCK2PRKACASGK1AKT1 | |
| SCHEMBL2557279 | 0.86 | ROCK1 (1.00) | ROCK1ROCK2PRKACA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9221808-B2 | Pyridylthiazole-based ureas as inhibitors of Rho associated protein kinase (ROCK) and methods of use | H. LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE, INC. (US) | 2015-12-29 | — | — | US | disclosed |
| US-9221808-B2 | Pyridylthiazole-based ureas as inhibitors of Rho associated protein kinase (ROCK) and methods of use | H. LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE, INC. (US) | 2015-12-29 | — | — | US | disclosed |
| US-9221808-B2 | Pyridylthiazole-based ureas as inhibitors of Rho associated protein kinase (ROCK) and methods of use | H. LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE, INC. (US) | 2015-12-29 | — | — | US | disclosed |
| US-20130059839-A1 | PYRIDYLTHIAZOLE-BASED UREAS AS INHIBITORS OF RHO ASSOCIATED PROTEIN KINASE (ROCK) AND METHODS OF USE | H. LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE, INC. (US) | 2013-03-07 | — | — | US | disclosed |
| US-20130059839-A1 | PYRIDYLTHIAZOLE-BASED UREAS AS INHIBITORS OF RHO ASSOCIATED PROTEIN KINASE (ROCK) AND METHODS OF USE | H. LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE, INC. (US) | 2013-03-07 | — | — | US | disclosed |
| US-20130059839-A1 | PYRIDYLTHIAZOLE-BASED UREAS AS INHIBITORS OF RHO ASSOCIATED PROTEIN KINASE (ROCK) AND METHODS OF USE | H. LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE, INC. (US) | 2013-03-07 | — | — | US | disclosed |
| WO-2011130740-A2 | PYRIDYLTHIAZOLE-BASED UREAS AS INHIBITORS OF RHO ASSOCIATED PROTEIN KINASE (ROCK) AND METHODS OF USE | H. LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE, INC. (US) | 2011-10-20 | — | — | WO | disclosed |
| WO-2011130740-A2 | PYRIDYLTHIAZOLE-BASED UREAS AS INHIBITORS OF RHO ASSOCIATED PROTEIN KINASE (ROCK) AND METHODS OF USE | H. LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE, INC. (US) | 2011-10-20 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130059839-A1 | PYRIDYLTHIAZOLE-BASED UREAS AS INHIBITORS OF RHO ASSOCIATED PROTEIN KINASE (ROCK) AND METHODS OF USE | ROCK1, ROCK2, CIT | ROCK1 1/4885ROCK2 2/4885PRKACA 91/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.